As the marijuana stock market attempts to pick itself up after a difficult growing up summer period, investors are looking for potential upticks of the sector before the end of 2019.

With stocks down and a shifting sentiment, the view on the short term outlook for the marijuana market has turned grim. However, a few key developments and the long-run aspect of the market itself continue to keep experts interested.


The play of the US market has also aided to some of the remaining positive position attached to this stock market.

The Investing News Network (INN) offers a look ahead at the remainder of 2019 for this sector and what investors can expect according to a variety of experts.

Cannabis market predictions: US market potential offers opportunity for struggling investors

As part of their monthly commentary to investors, the managers of the NinePoint Partners Alternative Health Fund said the sector still has a long runway despite the currently seen performance in the stock market.

“It is our view that the equity values of many of the leading names in the North American cannabis sector do not reflect the strength of the underlying businesses they represent,” wrote Charles Taerk, president and CEO of Faircourt Asset Management, and Doug Waterson, CFO and portfolio manager with Faircourt Asset Management.

According to the duo, the addressable market in the US should help to combat the fear any investors should have over the lack of federal marijuana policy in the country.

Matthew Pallotta, equity research analyst at Echelon Wealth Partners covering US names, previously told INN he expects to see multi-state operator (MSO) firms continue to face a discount in price and valuation compared to the Canadian counterparts.

“I think the discount is probably going to close regardless once people start seeing the revenue numbers these businesses are putting up,” Pallotta told INN.

Pallotta also pointed out that interest from large institutional money based in the US is only rising for cannabis. However, that interest remains on the sidelines due to the federal rules around the drug and its investment.

The team at Faircourt Asset Management had previously indicated the discount seen for MSOs compared to Canadian firms ranged from 60 percent to 70 percent averages during the spring, while in September that continued around the 40 percent to 50 percent range.

Cannabis market predictions: Are listing requirement changes on the horizon?

As an attempt to update the rulings from exchange regulators, an MSO executive held meetings with three prominent North American exchanges looking for a potential critical development in the space.

During the Canaccord US Cannabis Symposium event, Curaleaf Holdings (CSE:CURA,OTCQX:CURLF) Chairman Boris Jordan said he had met operators from the TMX Group (TSX:X) — the managers of the Toronto Stock Exchange (TSX) and the TSX Venture Exchange — as well as from the New York Stock Exchange and the NASDAQ.

While this specific meeting was neither confirmed nor denied by the TMX to INN, the exchange indicated it regularly looks at the evolution of marijuana policy.

Despite no confirmation of an actual rule change, it could prove interesting for investors to have these open conversations about the potential for MSOs to invade senior listing exchanges.

“I definitely think the TMX Group is probably looking at it going, ‘We missed out on a tremendous amount of financings. We missed out on a tremendous amount of new issues, listings. And these are real businesses,’” Josh Mann, president of Cannabis One Holdings (CSE:CBIS), told INN.

The change in investment has led to those still bullish on the space at large to adjust their thinking exploring the marketplace.

According to Elliot Johnson, chief investment officer with Evolve Funds Group, he’s excited to add positions in undervalued names as the sector is oversold.

“The companies that lead us out of this bear market will be in a much better position to succeed in 2020,” said Johnson. “We must continue to be active and opportunistic during this period of transition for this sector.”

Johnson also manages the Evolve Marijuana Fund (TSX:SEED) and the Evolve US Marijuana ETF (NEO:USMJ).

Cannabis market predictions: Could edibles and infused items kickstart Canadian markets?

While Canada approaches the legalization of novelty infused ingestible cannabis products — including vapes and beverages — these won’t go on sale until later in December.

Investors are excited for what the entry of these product categories will have on the Canadian market sales numbers; several large-scale producers have continued to struggle with establishing brands and having wide open retail options at their disposal.

Johnson told INN the legalization effect will draw some attention to the Canadian market despite the fact sales numbers won’t be posted until 2020.

Many players of the marijuana industry have made clear their intentions of offering a wide array of these products, including the potential for cannabis infused beverages.

Emma Andrews, chief commercial officer of BevCanna (CSE:BEV), told INN the beverage opportunity will offer an equal starting line for all producers involved.

The executive added the Canadian market will have critical advantages to the existing US cannabis drink market; thanks to the federal legalization, it may attract new consumers into trying these items.

“The quality bar is a lot higher for what we can expect out of the Canadian marketplace,” Andrews told INN.

Cannabis market predictions: Investor takeaway

As the marijuana market prepares for the last few months of the year, investors are looking for a turn in the sentiment that has affected these stocks.

The legalization of edibles in Canada and the activity of the SAFE Banking Act in the US are often pointed as natural markers for the stock market to get going again. At the same time, some experts want investors to get used to the long term operational plans rather than expect constant significant drivers.

Narbe Alexandrian, president and CEO of Canopy Rivers (TSX:RIV,OTC Pink:CNPOF), previously told INN the market is currently a great buying opportunity for investors.

“In my perspective this is an awesome buying opportunity if you truly believe this is going to be a US$50 billion industry,” he said.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: BevCanna is a client of the Investing News Network. This article is not paid-for content. 

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less